EISAI CO LTD (ESAIY:OTCMKTS)
$7.95 0.1 (1.2739%)
Analysed EISAI CO LTD (ESAIY:OTCMKTS) News Sources
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
15-09-2026
yahoo.com
Leqembi® Pen subcutaneous formulation approved in Japan
16-09-2026
yahoo.com
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data
23-09-2026
yahoo.com
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
28-09-2026
yahoo.com
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
28-09-2026
yahoo.com
eClinical Solutions Turns Clinical Data Intelligence Into Action at ENGAGE 2026
08-10-2026
yahoo.com
Eisai Deepens Its Oncology Evidence Base at ESMO Congress 2026
15-10-2026
yahoo.com
Sales of Leqembi® totaled 32.2 billion yen in the third quarter 2026
28-10-2026
yahoo.com
Eisai to Present New Five-Year Lecanemab Data and Real-World Alzheimer's Disease Research at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference
29-10-2026
yahoo.com
New clinical data on lecanemab to be presented at CTAD conference 2026
30-10-2026
yahoo.com
What is the current price of EISAI CO LTD (ESAIY:OTCMKTS)?
The current price of EISAI CO LTD (ESAIY:OTCMKTS) is $7.95.
EISAI CO LTD (ESAIY:OTCMKTS) absolute price change since previous trading day?
The absolute price change of EISAI CO LTD (ESAIY:OTCMKTS) since the previous trading day is $0.1.
EISAI CO LTD (ESAIY:OTCMKTS) percentage price change since previous trading day?
The percentage price change of EISAI CO LTD (ESAIY:OTCMKTS) since the previous trading day is 1.2739%.
What is the most recent average sentiment score for EISAI CO LTD (ESAIY:OTCMKTS)?
The most recent average sentiment score for EISAI CO LTD (ESAIY:OTCMKTS) is 76 out of 100.
What is the most recent average sentiment for EISAI CO LTD (ESAIY:OTCMKTS)?
The most recent sentiment for EISAI CO LTD (ESAIY:OTCMKTS) is .
SEC-8K** Filing Available For EISAI CO LTD (ESAIY:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.